DING
2.9.2021 13:02:11 CEST | Business Wire | Press release
Ding , the world’s largest mobile top-up service, is pleased to announce that it has agreed to sell a majority stake to Pollen Street Capital Private Equity (“Pollen Street”). Pollen Street Capital, a London-based, independent, alternative investment management company, will take a majority stake in the company, in partnership with a substantial investment from the existing founder Mark Roden. The transaction is expected to complete in September.
Commenting on the announcement, Mark Roden, Founder and Chief Executive of Ding said: “We are delighted to announce the investment by Pollen Street Capital. The addition of a strategic investor to our company marks an important milestone for Ding and sets us up for significant growth. Sixteen years ago, we set out with a mission to solve a real problem, to simplify how people separated from their loved ones could stay connected to those back home. At that time, the process was cumbersome and inefficient and today through Ding’s platform we have transformed how people stay connected. We are proud that we are now the global leader and have earned the trust of millions of customers all over the world.”
Founded in 2006 by Mark Roden, Ding is the global leader in international top-up and credit transfers, offering customers the ability to top-up online, on the Ding app, via partners through the Ding API and in over 600,000 retail stores all over the world. Ding now serves millions of customers around the world – who have sent almost a half a billion tops-ups since we began. Pollen Street’s investment will support Ding to continue its strong growth trajectory, expand its technology platform, develop new products and expand into new geographies which will help the Company grow its global customer base and to build out the critical social purpose of keeping communities and families connected.
He added: “Over the years we have explored different investment partners and opportunities but we ultimately chose Pollen Street Capital due to their understanding of our vision for the business, but also due to their extensive and deep expertise in impact investing. We continue to be a socially driven company and we felt that in Pollen Street we had a partner that shared our values.”
He continued: “I would like to thank all our employees past and present who have helped build Ding to become the market leader. With 6 billion prepaid phones in the world and an ever-increasing demand for mobile data there is a significant market opportunity to offer more products and services to current and future customers.”
Ian Gascoigne, Partner at Pollen Street, said: “We are delighted to welcome Mark and his team to the Pollen Street portfolio. Ding has demonstrated an impressive track record and we look forward to partnering with the team to accelerate this growth and maximising the potential of Ding’s multi-channel top-up ecosystem during our investment period. Ding exemplifies Pollen Street’s investment strategy of identifying market leading technology businesses, whose propositions can be enhanced through further investment into technology and an increasing use of data. Ding also represents our commitment to Invest With Impact. As a global platform that connects friends, family, and dispersed communities across the world, Ding allows its customers to send mobile credit and data through a simple, safe, and convenient top-up service. In doing so, Ding fosters closer links and community ties between its users whilst promoting financial inclusion and global connectivity through its highly accessible and easy to use platform.”
Ding was advised by Jefferies, Davis Polk, A&L Goodbody, KPMG and PWC. Pollen Street was advised by Keefe, Bruyette & Woods (a Stifel Company), McCann FitzGerald, Buckley and Deloitte.
Financial terms of the deal were not disclosed.
***ENDS***
About: Ding.com
About: Pollen Street Capital
View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005401/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
